IQVIA Institute for Human Data Science -
CAR T-cell therapies have shown substantial efficacy in several haematological conditions and hold the potential for transformative benefits in other difficult to treat diseases. In this report, the current health system capacity for delivering CAR T-cell therapies to patients was assessed in seven countries (Australia, Canada, France, Germany, Italy, Spain, the United Kingdom), to include reimbursement and funding, patient referral, treatment, and long-term follow-up. This report provides background on the complex CAR T-cell therapy patient journey from patient identification and referral to long-term monitoring, and estimates CAR T-cell therapy utilisation in a subset of countries.